

The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0)

Submission date 23/04/2010	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 23/04/2010	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 17/07/2025	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-two-surgical-treatments-for-early-mouth-cancer>

Contact information

Type(s)

Scientific

Contact name

Ms Fran Ridout

Contact details

Saving Faces
1st Floor Grove Building
Mile End Hospital
275 Bancroft Road
London
United Kingdom
E1 4DG
+44 20 8223 8049
send@savingfaces.co.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00571883

Protocol serial number

2069

Study information

Scientific Title

The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0)

Acronym

SEND

Study objectives

1. To determine whether the use of a selective neck dissection used electively (hereafter referred to as SEND) on all patients presenting with T1 and T2 tumours and no clinical evidence of neck metastasis (N0) improves survival, disease-free survival and loco-regional disease control rates
2. To determine how SEND and complex reconstruction affect quality of life (QoL) and mental health
3. To determine whether the use of SEND on all patients presenting with T1 and T2 tumours and clinically N0 necks represents a cost-effective use of resources

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee North East – Northern & Yorkshire, 11/11/2006, ref: 06/MRE03/69

Primary study design

Interventional

Study design

Randomised interventional treatment trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Head and Neck Cancer; Disease: Head and Neck

Interventions

The trial will be a two-arm randomized trial:

Arm A: Patients will be allocated to have resection of the primary tumour with neck dissection

Arm B: Patients will be allocated to have resection of the primary tumour only

Follow up length: 96 months

Study entry: single randomisation only

Intervention Type

Other

Phase

Phase IV

Primary outcome(s)

Overall survival

Key secondary outcome(s)

1. Disease-free survival
2. Local and regional recurrence
3. Completeness of resection

Completion date

20/06/2026

Eligibility

Key inclusion criteria

1. Patients with oral squamous cell carcinoma (OSCC) measuring 1 to 3 cm at the primary site (ICD9 codes: 141, 143, 144, 145, 146, 149)
2. No clinical or preoperative imaging evidence of nodal involvement in the neck (N0 neck)
3. Surgery is the primary mode of treatment
4. Age 16 years and over, either sex
5. Capable of giving written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

16 Years

Sex

All

Total final enrolment

596

Key exclusion criteria

1. Cancer of the lip (ICD9 code 140)
2. Previous head and neck tumour
3. Other synchronous tumour
4. Technical, medical or anaesthetic difficulties which preclude patients being entered into one of the trial arms

5. Where the surgeon assesses that the patient needs reconstruction that necessitates opening the neck
6. Those patients whom the multi-disciplinary team meeting considered to be medically, socially or psychiatrically unfit for surgery as first line treatment
7. Those patients where the patient expresses a preference for non-surgical treatment

Date of first enrolment

03/01/2007

Date of final enrolment

27/07/2015

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

St. Bartholomews Hospital

W Smithfield

London

United Kingdom

EC1A 7BE

Sponsor information

Organisation

Queen Mary University of London

ROR

<https://ror.org/026zzn846>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2019	12/06/2020	Yes	No
Plain English results			25/10/2022	No	Yes